Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672305 | 0.76 | MTNR1B (0.47) | — | |
| SCHEMBL15680239 | 0.76 | TP53 (0.40) | SRCGPR35ALDH1A1 | |
| SCHEMBL12344901 | 0.76 | ALDH1A1 (0.56) | SRCGPR35ALDH1A1 | |
| SCHEMBL19426037 | 0.73 | SRC (0.44) | SRCHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL3882600 | 0.72 | SRC (0.45) | SRCGPR35PRKACAPRKACGPRKACB | |
| SCHEMBL9321255 | 0.72 | LMNA (0.51) | SRCGPR35ALDH1A1 | |
| SCHEMBL17191916 | 0.72 | SCN9A (0.37) | SRCGPR35PRKACAPRKACGPRKACB | |
| SCHEMBL19426082 | 0.72 | SRC (0.36) | SRCGPR35HTR2B | |
| SCHEMBL646254 | 0.70 | GPR84 (0.55) | HTR2AALDH1A1 | |
| SCHEMBL15992161 | 0.69 | KDM4E (0.46) | SRCGPR35PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-7790762-B2 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH HEALTH (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2217259-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Health (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1562563-B1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH HEALTH (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009052411-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7498047-B2 | Methods for treatment of thiol-containing compound deficient conditions | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-11 | — | — | US | disclosed |
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1562563-A4 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NAT JEWISH MED & RES CENTER (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1562563-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | National Jewish Medical and Research Center (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004042020-A2 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135585-A1 | Compounds and methods for thiol-containing compound efflux and cancer treatment | ABCC1, ABCC2, ABCB1 | SRC 3208/4885GPR35 1817/4885PRKACA 3682/4885 |
| US-20040087527-A1 | Cystic fibrosis therapy; ATP-binding cassette transport modulation; glutathione concentration in epithelial lining fluid of lower respiratory tract | ABCC1, CFTR, ABCC2 | SRC 3927/4885GPR35 1553/4885PRKACA 2625/4885 |
| US-20080221029-A1 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS | ABCC1, SLC47A2, SLC47A1 | SRC 3000/4885GPR35 2209/4885PRKACA 1457/4885 |
| US-20060058245-A1 | Identifying a subject at risk of developing Beryllium Disease; contacting cells with an agent to increase transport of thiol-containing compound; modulating secretion of thiol-containing compound(s); attenuating the disease | ABCC2, CFTR, ABCC1 | SRC 4599/4885GPR35 722/4885PRKACA 1984/4885 |
| US-20140162986-A1 | Methods for treatment of thiol-containing compound deficient conditions | ABCC1, CFTR, SLC47A1 | SRC 4464/4885GPR35 2988/4885PRKACA 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.